{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:11:04Z","timestamp":1769861464306,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T00:00:00Z","timestamp":1582588800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1094708"],"award-info":[{"award-number":["1094708"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s10787-020-00694-7","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T05:31:22Z","timestamp":1582608682000},"page":"1395-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Better outcomes for patients with gout"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6045-6937","authenticated-orcid":false,"given":"Richard","family":"Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-564X","authenticated-orcid":false,"given":"Amy","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garry","family":"Graham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-5593","authenticated-orcid":false,"given":"Eindra","family":"Aung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-1893","authenticated-orcid":false,"given":"Mathew","family":"Coleshill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,25]]},"reference":[{"key":"694_CR1","doi-asserted-by":"crossref","first-page":"i51","DOI":"10.1093\/rheumatology\/kex421","volume":"57","author":"A Abhishek","year":"2018","unstructured":"Abhishek A, Doherty M (2018) Education and non-pharmacological approaches for gout. Rheumatol (Oxford) 57:i51\u2013i58","journal-title":"Rheumatol (Oxford)"},{"key":"694_CR2","first-page":"529","volume":"56","author":"A Abhishek","year":"2017","unstructured":"Abhishek A, Jenkins W, La-Crette J, Fernandes G, Doherty M (2017) Long-term persistence and adherence on urate-lowering treatment can be maintained in primary care\u20145-year follow-up of a proof-of-concept study. Rheumatology 56:529\u2013533","journal-title":"Rheumatology"},{"key":"694_CR3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P (2017) Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med 15:123","journal-title":"BMC Med"},{"key":"694_CR4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1136\/annrheumdis-2013-203600","volume":"73","author":"C Batt","year":"2014","unstructured":"Batt C, Phipps-Green AJ, Black MA, Cadzow M, Merriman ME, Topless R, Gow P, Harrison A, Highton J, Jones P et al (2014) Sugar-sweetened beverage consumption: a risk factor for prevalent gout with SLC2A9 genotype-specific effects on serum urate and risk of gout. Ann Rheum Dis 73:2101\u20132106","journal-title":"Ann Rheum Dis"},{"key":"694_CR5","first-page":"2429","volume":"31","author":"GC Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA (2004) Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 31:2429\u20132432","journal-title":"J Rheumatol"},{"key":"694_CR6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/acr.23562","volume":"70","author":"Z Bowen-Davies","year":"2018","unstructured":"Bowen-Davies Z, Muller S, Mallen CD, Hayward RA, Roddy E (2018) Gout severity, socioeconomic status, and work absence: a cross-sectional study in primary care. Arthritis Care and Research 70:1822\u20131828","journal-title":"Arthritis Care and Research"},{"key":"694_CR7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1592\/phco.28.4.437","volume":"28","author":"BA Briesacher","year":"2008","unstructured":"Briesacher BA, Andrade SE, Fouayzi H, Chan KA (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28:437\u2013443","journal-title":"Pharmacotherapy"},{"key":"694_CR8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","volume":"350","author":"HK Choi","year":"2004","unstructured":"Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350:1093\u20131103","journal-title":"N Engl J Med"},{"key":"694_CR9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12875-018-0744-3","volume":"19","author":"AB Counsell","year":"2018","unstructured":"Counsell AB, Nguyen AD, Baysari MT, Kannangara DRW, McLachlan AJ, Day RO (2018) Exploring current and potential roles of Australian community pharmacists in gout management: a qualitative study. BMC Fam Pract 19:54","journal-title":"BMC Fam Pract"},{"key":"694_CR10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, Barclay C, Doherty S, Duley L, Hatton R et al (2018) Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet 392:1403\u20131412","journal-title":"Lancet"},{"issue":"4","key":"694_CR11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3899\/jrheum.170806","volume":"45","author":"MM Elfishawi","year":"2017","unstructured":"Elfishawi MM, Zleik N, Kvrgic Z, Michet CJ, Jr Crowson CS, Matteson EL, Bongartz T (2017) The rising incidence of gout and the increasing burden of comorbidities: a population-based study over 20 years. J Rheumatol 45(4):574\u2013579","journal-title":"J Rheumatol"},{"key":"694_CR12","first-page":"28","volume":"227","author":"A Fernon","year":"2016","unstructured":"Fernon A, Nguyen A, Baysari M, Day R (2016) A user-centred approach to designing an etool for gout management. Stud Health Technol Inform 227:28\u201333","journal-title":"Stud Health Technol Inform"},{"key":"694_CR13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12891-015-0661-8","volume":"16","author":"TJ Flynn","year":"2015","unstructured":"Flynn TJ, Cadzow M, Dalbeth N, Jones PB, Stamp LK, Hindmarsh JH, Todd AS, Walker RJ, Topless R, Merriman TR (2015) Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. BMC Musculoskelet Disord 16:196","journal-title":"BMC Musculoskelet Disord"},{"key":"694_CR14","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/bcp.12126","volume":"76","author":"GG Graham","year":"2013","unstructured":"Graham GG, Kannangara DR, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO (2013) Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Br J Clin Pharmacol 76:932\u2013938","journal-title":"Br J Clin Pharmacol"},{"key":"694_CR15","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","volume":"76","author":"KR Hande","year":"1984","unstructured":"Hande KR, Noone RM, Stone WJ (1984) Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 76:47\u201356","journal-title":"Am J Med"},{"key":"694_CR16","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald TM et al (2017) The British society for rheumatology guideline for the management of Gout. Rheumatol 56:e1\u2013e20","journal-title":"Rheumatol"},{"issue":"1092","key":"694_CR17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/postgradmedj-2015-133920","volume":"92","author":"A Jeyaruban","year":"2016","unstructured":"Jeyaruban A, Soden M, Larkins S (2016) General practitioners\u2019 perspectives on the management of gout: a qualitative study. Postgrad Med J 92(1092):603\u2013607","journal-title":"Postgrad Med J"},{"issue":"9","key":"694_CR18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1111\/bcp.13307","volume":"83","author":"DRW Kannangara","year":"2017","unstructured":"Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD (2017) Individualising the dose of allopurinol in patients with gout. Br J Clin Pharmacol 83(9):2015\u20132026","journal-title":"Br J Clin Pharmacol"},{"key":"694_CR19","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5694\/j.1326-5377.1993.tb137784.x","volume":"159","author":"TV Kot","year":"1993","unstructured":"Kot TV, Day RO, Brooks PM (1993) Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs? Med J Aust 159:182\u2013184","journal-title":"Med J Aust"},{"issue":"11","key":"694_CR20","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649\u2013662","journal-title":"Nat Rev Rheumatol"},{"key":"694_CR21","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.2196\/humanfactors.8096","volume":"4","author":"AY Lau","year":"2017","unstructured":"Lau AY, Piper K, Bokor D, Martin P, Lau VS, Coiera E (2017) Challenges during implementation of a patient-facing mobile app for surgical rehabilitation: feasibility study. JMIR Hum Factors 4:e31","journal-title":"JMIR Hum Factors"},{"key":"694_CR22","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1016\/S2665-9913(19)30078-5","volume":"1","author":"J Li","year":"2019","unstructured":"Li J, Badve SV, Zhou Z, Rodgers A, Day R, Oh R, Lee M, Perkovic V, de Zeeuw D, Mahaffey KW et al (2019) The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatol 1:e220\u2013e228","journal-title":"Lancet Rheumatol"},{"key":"694_CR23","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1136\/annrheumdis-2016-210352","volume":"76","author":"T Neogi","year":"2017","unstructured":"Neogi T, Dalbeth N, Stamp L, Castelar G, Fitzgerald J, Gaffo A, Mikuls TR, Singh J, Vazquez-Mellado J, Edwards NL (2017) Renal dosing of allopurinol results in suboptimal gout care. Ann Rheum Dis 76:e1","journal-title":"Ann Rheum Dis"},{"key":"694_CR24","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijmedinf.2016.06.021","volume":"94","author":"AD Nguyen","year":"2016","unstructured":"Nguyen AD, Baysari MT, Kannangara DR, Tariq A, Lau AY, Westbrook JI, Day RO (2016) Mobile applications to enhance self-management of gout. Int J Med Inform 94:67\u201374","journal-title":"Int J Med Inform"},{"key":"694_CR25","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.2196\/mhealth.9811","volume":"6","author":"AD Nguyen","year":"2018","unstructured":"Nguyen AD, Frensham LJ, Wong MX, Meslin SM, Martin P, Lau AY, Baysari MT, Day RO (2018) mHealth app patient testing and review of educational materials designed for self-management of gout patients: descriptive qualitative studies. JMIR Mhealth Uhealth 6:e182","journal-title":"JMIR Mhealth Uhealth"},{"key":"694_CR26","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar1906","volume":"8","author":"G Nuki","year":"2006","unstructured":"Nuki G, Simkin PA (2006) A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 8:S1\u2013S1","journal-title":"Arthritis Res Ther"},{"key":"694_CR27","first-page":"132","volume":"77","author":"F P\u00e9rez-Ruiz","year":"2018","unstructured":"P\u00e9rez-Ruiz F, So A, Kandaswamy P, Karra R, Kelton K, Perk S, Bardin T (2018) OP0162-HPR Estimating health-related quality of life for gout patients: a post-hoc analysis of utilities from the clear trials. Ann Rheum Dis 77:132\u2013132","journal-title":"Ann Rheum Dis"},{"key":"694_CR28","first-page":"j1794","volume":"357","author":"SK Rai","year":"2017","unstructured":"Rai SK, Fung TT, Lu N, Keller SF, Curhan GC, Choi HK (2017) The dietary approaches to stop hypertension (dash) diet, western diet, and risk of gout in men: prospective cohort study. BMJ 357:j1794","journal-title":"BMJ"},{"key":"694_CR29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s40264-013-0084-0","volume":"36","author":"SN Ramasamy","year":"2013","unstructured":"Ramasamy SN, Korb-Wells CS, Kannangara DRW, Smith MWH, Wang N, Roberts DM, Graham GG, Williams KM, Day RO (2013) Allopurinol hypersensitivity: a systematic review of all published cases, 1950\u20132012. Drug Saf 36:953\u2013980","journal-title":"Drug Saf"},{"key":"694_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1759720X18807117","volume":"10","author":"K Ramsubeik","year":"2018","unstructured":"Ramsubeik K, Ramrattan LA, Kaeley GS, Singh JA (2018) Effectiveness of healthcare educational and behavioral interventions to improve gout outcomes: a systematic review and meta-analysis. Ther Adv Musculoskelet Dis 10:235\u2013252","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"694_CR31","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","volume":"79","author":"P Richette","year":"2020","unstructured":"Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castaneda J, Coyfish M, Guillo S, Jansen T, Janssens H et al (2020) 2018 updated European league against rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis 79:31\u201338","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"694_CR32","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.3390\/jcm8122150","volume":"8","author":"S Rodriguez-Martin","year":"2019","unstructured":"Rodriguez-Martin S, de Abajo FJ, Gil M, Gonzalez-Bermejo D, Rodriguez-Miguel A, Barreira-Hernandez D, Mazzucchelli R, Garcia-Lledo A, Garcia-Rodriguez LA (2019) Risk of acute myocardial infarction among new users of allopurinol according to serum urate level: a nested case-control study. J Clin Med 8(12):2150","journal-title":"J Clin Med"},{"key":"694_CR33","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"L Scheepers","year":"2018","unstructured":"Scheepers L, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A (2018) Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum 47:689\u2013702","journal-title":"Semin Arthritis Rheum"},{"key":"694_CR34","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","volume":"73","author":"E Smith","year":"2014","unstructured":"Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, Woolf A, March L (2014) The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis 73:1470\u20131476","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"694_CR35","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N (2017) A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 76(9):1522\u20131528","journal-title":"Ann Rheum Dis"},{"key":"694_CR36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13075-018-1755-0","volume":"20","author":"LK Stamp","year":"2018","unstructured":"Stamp LK, Chapman PT, Barclay ML, Horne A, Frampton C, Tan P, Drake J, Dalbeth N (2018) How much allopurinol does it take to get to target urate? Comparison of actual dose with creatinine clearance-based dose. Arthritis Res Ther 20:255","journal-title":"Arthritis Res Ther"},{"issue":"2019","key":"694_CR37","first-page":"1378","volume":"85.6","author":"LK Stamp","year":"2018","unstructured":"Stamp LK, Wright DFB, Dalbeth N (2018b) Restricting maintenance allopurinol dose according to kidney function in patients with gout is inappropriate! Br J Clin Pharmacol 85.6(2019):1378\u20131379","journal-title":"Br J Clin Pharmacol"},{"key":"694_CR38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40271-016-0184-x","volume":"10","author":"S Tatlock","year":"2017","unstructured":"Tatlock S, Rudell K, Panter C, Arbuckle R, Harrold LR, Taylor WJ, Symonds T (2017) What outcomes are important for gout patients? In-depth qualitative research into the gout patient experience to determine optimal endpoints for evaluating therapeutic interventions. Patient 10:65\u201379","journal-title":"Patient"},{"issue":"1","key":"694_CR39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3899\/jrheum.150607","volume":"43","author":"S Vaccher","year":"2015","unstructured":"Vaccher S, Kannangara DRW, Baysari MT, Reath J, Zwar N, Williams KM, Day RO (2015) Barriers to care in gout: from prescriber to patient. J Rheum 43(1):144\u2013149","journal-title":"J Rheum"},{"key":"694_CR40","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","volume":"6","author":"B Waldman","year":"2018","unstructured":"Waldman B, Ansquer J-C, Sullivan DR, Jenkins AJ, McGill N, Buizen L, Davis TME, Best JD, Li L, Feher MD et al (2018) Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes and Endocrinol 6:310\u2013318","journal-title":"Lancet Diabetes and Endocrinol"},{"key":"694_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez476","author":"Y Xia","year":"2019","unstructured":"Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y (2019). Global, regional and national burden of gout, 1990\u20132017: a systematic analysis of the global burden of disease study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/kez476","journal-title":"Rheumatology (Oxford)"},{"key":"694_CR42","doi-asserted-by":"crossref","first-page":"e38123","DOI":"10.1371\/journal.pone.0038123","volume":"7","author":"L Zgaga","year":"2012","unstructured":"Zgaga L, Theodoratou E, Kyle J, Farrington SM, Agakov F, Tenesa A, Walker M, McNeill G, Wright AF, Rudan I et al (2012) The association of dietary intake of purine-rich vegetables, sugar-sweetened beverages and dairy with plasma urate, in a cross-sectional study. PLoS ONE 7:e38123","journal-title":"PLoS ONE"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10787-020-00694-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00694-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,24]],"date-time":"2021-02-24T01:16:33Z","timestamp":1614129393000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10787-020-00694-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,25]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["694"],"URL":"https:\/\/doi.org\/10.1007\/s10787-020-00694-7","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,25]]},"assertion":[{"value":"27 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}